Agomelatine

Agomelatine

SCHEMBL2454293

Br.COc1ccc2cccc(CCNC(C)=O)c2c1.O

nearest known ligand 0.95

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

HTR2CMTNR1AMTNR1B

The experimentally established mechanism targets of Agomelatine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
MTNR1A known ✓ P48039 18/20 0.95
MTNR1B known ✓ P49286 9/20 0.95
HTR2C known ✓ P28335 1/20 0.95
HTR2B P41595 1/20 0.95
NQO2 P16083 1/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Agomelatine SCHEMBL27855409 0.99 MTNR1A (0.97) MTNR1AMTNR1BHTR2CHTR2BNQO2
Agomelatine SCHEMBL28116100 0.99 MTNR1A (0.97) MTNR1AMTNR1BHTR2CHTR2BNQO2
Agomelatine SCHEMBL2371196 0.97 MTNR1A (0.95) MTNR1AMTNR1BHTR2CHTR2BNQO2
Agomelatine SCHEMBL27215745 0.97 MTNR1A (0.95) MTNR1AMTNR1BHTR2CHTR2BNQO2
Agomelatine SCHEMBL1158495 0.97 MTNR1A (1.00) MTNR1AMTNR1BHTR2CHTR2BNQO2
Agomelatine SCHEMBL27844916 0.97 MTNR1A (1.00) MTNR1AMTNR1BHTR2CHTR2BNQO2
Agomelatine SCHEMBL29930659 0.97 MTNR1A (1.00) MTNR1AMTNR1BHTR2CHTR2BNQO2
Agomelatine SCHEMBL114476 0.97 MTNR1A (1.00) MTNR1AMTNR1BHTR2CHTR2BNQO2
Agomelatine SCHEMBL1289524 0.96 MTNR1A (0.97) MTNR1AMTNR1BHTR2CHTR2BNQO2
Agomelatine SCHEMBL28522576 0.96 MTNR1A (0.97) MTNR1AMTNR1BHTR2CHTR2BNQO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2547650-B1 AGOMELATINE HYDROBROMIDE HYDRATE AND PREPARATION THEREOF SERVIER LAB (FR) 2015-11-04 EP claimed
CN-102892749-B Agomelatine hydrobromide hydrate and preparation thereof SERVIER LAB 2014-11-05 CN claimed
US-8729132-B2 Agomelatine hydrobromide hydrate and preparation thereof LES LABORATOIRES SERVIER (FR) 2014-05-20 US claimed
EP-2547650-A1 AGOMELATINE HYDROBROMIDE HYDRATE AND PREPARATION THEREOF Les Laboratoires Servier (FR) 2013-01-23 EP claimed
CN-102892749-A Agomelatine hydrobromide hydrate and preparation thereof SERVIER LAB 2013-01-23 CN claimed
US-20130012592-A1 AGOMELATINE HYDROBROMIDE HYDRATE AND PREPARATION THEREOF LES LABORATOIRES SERVIER (FR) 2013-01-10 US claimed
WO-2011113363-A1 AGOMELATINE HYDROBROMIDE HYDRATE AND PREPARATION THEREOF LES LABORATOIRES SERVIER (FR) 2011-09-22 WO claimed
CN-102190595-A Agomelatine hydrogen bromide hydrate and preparation method thereof SHANGHAI INST PHARM INDUSTRY 2011-09-21 CN claimed
EP-2547650-B1 AGOMELATINE HYDROBROMIDE HYDRATE AND PREPARATION THEREOF SERVIER LAB (FR) 2015-11-04 EP disclosed
CN-102718675-B Agomelatine methanesulfonic acid complex and preparation method thereof SHANGHAI RIGHT HAND MEDICAL TECHNOLOGY DEV CO LTD 2015-03-25 CN disclosed
CN-102892749-B Agomelatine hydrobromide hydrate and preparation thereof SERVIER LAB 2014-11-05 CN disclosed
CN-102892749-B Agomelatine hydrobromide hydrate and preparation thereof SERVIER LAB 2014-11-05 CN disclosed
CN-102892749-B Agomelatine hydrobromide hydrate and preparation thereof SERVIER LAB 2014-11-05 CN disclosed
CN-102702008-B Agomelatine sulfuric acid composition and preparation method thereof SHANGHAI YOUSHOU PHARMACEUTICAL TECHNOLOGY DEV CO LTD 2014-05-28 CN disclosed
WO-2011113363-A1 AGOMELATINE HYDROBROMIDE HYDRATE AND PREPARATION THEREOF LES LABORATOIRES SERVIER (FR) 2011-09-22 WO disclosed
WO-2011113363-A1 AGOMELATINE HYDROBROMIDE HYDRATE AND PREPARATION THEREOF LES LABORATOIRES SERVIER (FR) 2011-09-22 WO disclosed
CN-102190595-A Agomelatine hydrogen bromide hydrate and preparation method thereof SHANGHAI INST PHARM INDUSTRY 2011-09-21 CN disclosed
CN-102190595-A Agomelatine hydrogen bromide hydrate and preparation method thereof SHANGHAI INST PHARM INDUSTRY 2011-09-21 CN disclosed
CN-102190595-A Agomelatine hydrogen bromide hydrate and preparation method thereof SHANGHAI INST PHARM INDUSTRY 2011-09-21 CN disclosed
CN-102190594-A Agomelatine hydrogen chloride hydrate and preparation method thereof SHANGHAI INST PHARM INDUSTRY 2011-09-21 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130012592-A1 AGOMELATINE HYDROBROMIDE HYDRATE AND PREPARATION THEREOF MC2R, MC5R, MC4R MTNR1A 23/4885MTNR1B 15/4885HTR2C 63/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.